An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Published:2012-02 Issue:3 Volume:48 Page:324-332
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Grünwald Viktor,Karakiewicz Pierre I.,Bavbek Sevil E.,Miller Kurt,Machiels Jean-Pascal,Lee Se-Hoon,Larkin James,Bono Petri,Rha Sun Young,Castellano Daniel,Blank Christian U.,Knox Jennifer J.,Hawkins Robert,Anak Oezlem,Rosamilia Marianne,Booth Jocelyn,Pirotta Nicoletta,Bodrogi István

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008

2. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors;Motzer;Cancer,2010

3. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J Natl Cancer Inst,2000

4. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2004

5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Kidney Cancer. Version 1.2011. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [accessed February 18, 2011].

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma;International Journal of Molecular Sciences;2021-06-11

2. Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma;Cancers;2020-10-06

3. Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment;Cancers;2020-09-21

4. Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM;Cancer Urology;2019-10-09

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

;Cancer Management and Research;2019-08